BioShares Biotechnology Performance

BioShares Biotechnology Clinical Trials -- USA Etf  

USD 30.55  0.05  0.16%

The organization shows Beta (market volatility) of -2.3353 which signifies that as returns on market increase, returns on owning BioShares Biotechnology are expected to decrease by larger amounts. On the other hand, during market turmoil, BioShares Biotechnology is expected to significantly outperform it.. Although it is vital to follow to BioShares Biotechnology historical returns, it is good to be conservative about what you can actually do with the information regarding equity current trending patterns. The philosophy towards foreseeing future performance of any etf is to evaluate the business as a whole together with its past performance including all available fundamental and technical indicators. We have found twenty-eight technical indicators for BioShares Biotechnology Clinical Trials which you can use to evaluate performance of the entity.
 Time Horizon     30 Days    Login   to change

BioShares Biotechnology Relative Risk vs. Return Landscape

If you would invest  2,739  in BioShares Biotechnology Clinical Trials on December 19, 2017 and sell it today you would earn a total of  316  from holding BioShares Biotechnology Clinical Trials or generate 11.54% return on investment over 30 days. BioShares Biotechnology Clinical Trials is generating 0.562% of daily returns assuming volatility of 1.751% on return distribution over 30 days investment horizon. In other words, 16% of equities are less volatile than the company and above 90% of equities are expected to generate higher returns over the next 30 days.
 Daily Expected Return (%) 
      Risk (%) 
Considering 30-days investment horizon, BioShares Biotechnology Clinical Trials is expected to generate 4.61 times more return on investment than the market. However, the company is 4.61 times more volatile than its market benchmark. It trades about 0.32 of its potential returns per unit of risk. The DOW is currently generating roughly 0.57 per unit of risk.

Price to Book

BioShares Biotechnology Price to Book
Based on latest financial disclosure the price to book indicator of BioShares Biotechnology Clinical Trials is roughly 1.75 times. This is 2.34% higher than that of the Bio Shares family, and 2.64% higher than that of Health category, The Price to Book for all etfs is 80.41% lower than the firm.
  to Book 
      BioShares Biotechnology Comparables 
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.

BioShares Biotechnology Daily Price Distribution

The median price of BioShares Biotechnology for the period between Tue, Dec 19, 2017 and Thu, Jan 18, 2018 is 28.73 with a coefficient of variation of 4.03. The daily time series for the period is distributed with a sample standard deviation of 1.16, arithmetic mean of 28.9, and mean deviation of 0.98. The Etf received some media coverage during the period.
21 

Risk-Adjusted Performance

Compared to the overall equity markets, risk-adjusted returns on investments in BioShares Biotechnology Clinical Trials are ranked lower than 21 (%) of all global equities and portfolios over the last 30 days.

One Month Efficiency

BioShares Biotechnology Sharpe Ratio = 0.321
Best
Portfolio
Best
Equity
Good Returns
Average Returns
Small ReturnsBBC
CashSmall
Risk
Average
Risk
High
Risk
Huge
Risk
Negative Returns

Estimated Market Risk

 1.75
  actual daily
 
 84 %
of total potential
  

Expected Return

 0.56
  actual daily
 
 10 %
of total potential
  

Risk-Adjusted Return

 0.32
  actual daily
 
 21 %
of total potential
  
Based on monthly moving average BioShares Biotechnology is performing at about 21% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of BioShares Biotechnology by adding it to a well-diversified portfolio.

Dividends

BioShares Biotechnology Dividends Analysis
Check BioShares Biotechnology dividend payout schedule and payment analysis over time. Analyze past dividends calendar and estimate annual dividend income
Check Dividends